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PCLINICAL RESEARCH Clinical Trial
The ABCD (Alternans Before
Cardioverter Defibrillator) Trial
Strategies Using T-Wave Alternans to
Improve Efficiency of Sudden Cardiac Death Prevention
Otto Costantini, MD,* Stefan H. Hohnloser, MD,† Malcolm M. Kirk, MD,‡ Bruce B. Lerman, MD,§
James H. Baker II, MD, Barathi Sethuraman, PHD,¶ Mary M. Dettmer, RN,*
David S. Rosenbaum, MD,* for the ABCD Trial Investigators
Cleveland, Ohio; Frankfurt, Germany; Providence, Rhode Island; New York, New York; Nashville, Tennessee;
and Sunnyvale, California
Objectives Because risk stratification with electrophysiological study (EPS) improves efficiency but is invasive, we sought to
determine whether noninvasive microvolt T-wave alternans (MTWA) testing could identify patients who benefit
from implantable cardioverter-defibrillators (ICDs) as well as EPS.
Background Prevention of sudden cardiac death on the basis of left ventricular ejection fraction (LVEF) alone is inefficient,
because most ICDs never deliver therapy.
Methods The ABCD (Alternans Before Cardioverter Defibrillator) trial is a multicenter prospective study that enrolled pa-
tients with ischemic cardiomyopathy (LVEF 0.40) and nonsustained ventricular tachycardia. All patients under-
went MTWA and EPS. ICDs were mandated if either test was positive.
Results Of 566 patients followed for a median of 1.9 years, 39 (7.5%) met the primary end point of appropriate ICD dis-
charge or sudden death at 1 year. As hypothesized, primary analysis showed that MTWA achieved 1-year posi-
tive (9%) and negative (95%) predictive values that were comparable to EPS (11% and 95%, respectively). In
addition, secondary analysis showed that at the pre-specified 1-year end point, event rates were significantly
higher in patients with both a positive MTWA-directed strategy (hazard ratio: 2.1, p  0.03) and a positive EPS-
directed strategy (hazard ratio: 2.4, p  0.007). Moreover, the event rate in patients with both negative MTWA
test and EPS was lower than in those with 2 positive tests (2% vs. 12%; p  0.017).
Conclusions The ABCD study is the first trial to use MTWA to guide prophylactic ICD insertion. Risk stratification strategies
using noninvasive MTWA versus invasive EPS are comparable at 1 year and complementary when applied in
combination. Strategies employing MTWA, EPS, or both might identify subsets of patients least likely to benefit
from ICD insertion. (Study to Compare TWA Test and EPS Test for Predicting Patients at Risk for Life-Threatening
Heart Rhythms [ABCD Study]; NCT00187291) (J Am Coll Cardiol 2009;53:471–9) © 2009 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.08.077f
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ccepted August 18, 2008.or sudden cardiac death (SCD) have demonstrated signif-
cant reductions in mortality after implantable cardioverter-
efibrillator (ICD) insertion (1,2). Despite the high thera-
eutic efficiency (4 ICDs/life saved) of this approach,
oncerns were raised that a negative EPS was not sufficient
See page 480
vidence to avoid ICD insertion (3). Moreover, it is im-
ractical to screen all patients at risk for SCD with EPS,
ecause it is invasive, expensive, and requires specialized
echnology and personnel. Recent randomized trials that
elected patients for ICD insertion on the basis of reduced
eft ventricular ejection fraction (LVEF) alone (4,5) also
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ABCD Trial February 10, 2009:471–9demonstrated an improvement in
mortality rates but did so with
relatively low therapeutic efficiency
(15 to 17 ICDs/life saved). Con-
sequently, although guidelines rec-
ommend prophylactic ICDs in
most patients with LVEF 0.35,
the majority of inserted ICDs
never deliver therapy (6). Con-
cerns regarding device compli-
cations, including worsening heart
failure, inappropriate shocks, and
device recalls, and the impact on
health care costs (7) have also
prompted a re-examination of this
strategy (8).
Electrophysiological markers
that, unlike LVEF, more directly
reflect arrhythmia substrates might
better identify patients who benefit
from ICD insertion. In fact, when
EPS is used in addition to low
VEF to risk-stratify patients, the cost effectiveness and
ortality reduction of ICDs double (9). Recently, microvolt
-wave alternans (MTWA), a subtle beat-to-beat oscillation
n the electrocardiogram’s T-wave amplitude, which has been
inked to an arrhythmogenic mechanism (10), has emerged as
promising noninvasive method for predicting SCD (11–13).
ts high negative predictive value (NPV) (12,14) is particularly
ttractive for use in primary prevention of SCD. Therefore, the
BCD (Alternans Before Cardioverter Defibrillator) trial was
esigned to test the hypothesis that, in patients with coronary
isease and a low LVEF, a noninvasive MTWA test would
erform at least as well as an invasive EPS in determining the
isk of SCD. In addition, we hypothesized that strategies
ncorporating a noninvasive MTWA test, either alone or in
ombination with EPS, would better identify patients likely to
enefit from ICD insertion compared with using LVEF alone.
ethods
atient population. Patients were enrolled from 43 centers
n the U.S., Germany, and Israel. Follow-up ended on June
0, 2006. Patients were eligible if they were 18 years old,
ad LVEF0.40 attributable to ischemic heart disease, and
ad nonsustained ventricular tachycardia (NSVT). Ischemic
eart disease was documented by a prior myocardial infarc-
ion, percutaneous coronary intervention, or coronary artery
ypass grafting or by angina with either a positive stress test
r a 50% occlusion of any coronary artery by angiography.
he LVEF was documented within 6 months of enrollment
y echocardiography, radionuclide, or contrast ventriculog-
aphy. The NSVT was documented by 24-h ambulatory
ecording within 6 months of enrollment and was defined as
n prior trials (15). Patients were excluded if they had
Abbreviations
and Acronyms
ATP  antitachycardia
pacing
EPS  electrophysiological
study
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
LVEF  left ventricular
ejection fraction
MTWA  microvolt T-wave
alternans
NPV  negative predictive
value
NSVT  nonsustained
ventricular tachycardia
PPV  positive predictive
value
SCD  sudden cardiac
deathnstable coronary artery disease, New York Heart Associa- tion functional class IV heart failure, prior cardiac arrest,
ustained ventricular arrhythmia, or unexplained syncope;
ere within 28 days of myocardial infarction, coronary
rtery bypass grafting, or percutaneous coronary interven-
ion; had permanent atrial fibrillation; or were taking an
ntiarrhythmic drug at baseline. All patients underwent
TWA testing and EPS within 28 days of each other.
TWA testing and analysis. The MTWA was measured
ith the spectral method by a graded exercise protocol.
igh-resolution electrocardiographic leads (Cambridge
eart, Inc., Bedford, Massachusetts) were placed in the
tandard 12-lead positions and in the X, Y, and Z orthog-
nal configuration. Beta-blocker drugs were withheld for
24 h before the MTWA test. The MTWA tests were
nterpreted with previously described criteria (16) by an
ndependent core laboratory blinded to clinical outcomes
nd the EPS results.
The primary analysis compared an “MTWA-directed”
trategy to “EPS-directed” strategy in predicting arrhythmic
vents. The “MTWA-directed” strategy was defined as
ositive (“high risk”) either if the MTWA test was positive
r if the MTWA test was indeterminate and the EPS was
ositive. The “MTWA-directed” strategy was defined as
egative (“low risk”) if the MTWA test was negative or if
he MTWA test was indeterminate and the EPS was
egative. This was intended to simulate a strategy where all
atients with reduced LVEF are screened noninvasively
ith an MTWA test and undergo additional risk stratifi-
ation with EPS only if the MTWA test were indetermi-
ate. Pre-specified secondary analyses were performed with
he standard definition of MTWA positivity (excluding
rom analysis patients with indeterminate results) and a
reviously validated definition (17) of patients with positive
r indeterminate MTWA as “MTWA-abnormal” and
hose with negative MTWA as “MTWA-normal.”
lectrophysiological testing and analysis. The EPS was
erformed and analyzed with established methods (15).
riefly, programmed ventricular stimulation used single,
ouble, and triple extra-stimuli from 2 right ventricular sites
ith minimum premature coupling interval of 180 ms. The
rotocol was terminated if sustained monomorphic ventric-
lar tachycardia or ventricular fibrillation was induced. An
ndependent core laboratory blinded to patient outcomes
nd to the results of the MTWA tests interpreted all EPS.
n EPS was positive (and therefore the “EPS-directed”
trategy was positive) if sustained monomorphic ventricular
achycardia was induced at a cycle length faster than 500 ms,
asting at least 30 s or causing hemodynamic compromise,
r if ventricular fibrillation or polymorphic ventricular
achycardia was induced by 1 or 2 extra-stimuli. Otherwise,
he EPS (and therefore the “EPS-directed” strategy) was
egative.
CD insertion and programming. An ICD insertion was
andated in all patients with either positive MTWA or
PS. Although strongly encouraged, ICD insertion was left
o the discretion of the investigators in patients with both
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February 10, 2009:471–9 ABCD Trialegative MTWA and EPS or an indeterminate MTWA
est and a negative EPS. The ICD programming was
re-specified for detection of ventricular tachyarrhythmias
single zone) exceeding 171 beats/min, with “shock only”
herapy at maximal outputs.
ollow-up and study end points. The follow-up period
egan immediately after the MTWA test and the EPS were
oth completed. Patients were followed at 6-month inter-
als for up to 2 years. If ICD therapy was delivered, the
atient was scheduled as quickly as possible to document the
vent.
The primary end point was defined a priori as either the
rst appropriate ICD discharge or SCD (as defined by the
inkle-Thaler classification) (18), at 1 year of follow-up.
n independent events committee, blinded to the results of
he MTWA test and EPS, reviewed the clinical history,
lectrocardiographic, and ICD data to assure appropriate
lassification of an event as an end point.
tudy design and statistical analysis. Because the main
bjective of the ABCD trial was to prove that a noninvasive
trategy of risk stratification for SCD was equal to (rather
han superior to) an invasive one, we chose a noninferiority
tudy design. The study was designed to prospectively
valuate whether the positive predictive value (PPV) and
PV of MTWA-directed ICD insertion was noninferior to
hat of EPS at 1 year of follow-up. The noninferiority
ut-point was defined as 10% for the PPV and NPV
ypotheses. A 2-step statistical model was employed to
stimate the power of the study with bootstrap methods. A
0% loss to follow-up was taken into account for the
urpose of calculating sample size. With 538 patients, the
ower for the primary hypotheses was 95% at the 5%
ignificance level.
Clinical characteristics were compared with the t test or
earson chi-square test as appropriate. The PPV and NPV
ere calculated on the basis of the Kaplan-Meier 1- and
-year event rates, and a nonparametric bootstrap method
as used to calculate standard errors. Sensitivity and spec-
ficity were calculated on the basis of actual event rates.
nalyses comparing the event rates in the positive and
egative groups were done with the log-rank test or Cox
roportional hazards model, and when appropriate, the Cox
roportional hazards model employed time-dependent co-
ariates to represent the time cut-off at which the EPS or
TWA test was no longer predictive. A 2-sided p  0.05
as considered statistically significant.
esults
atient characteristics. After screening 629 patients, 63
ere excluded for protocol violations (Fig. 1). The remain-
ng 566 patients were followed for 1.6  0.6 years (median
.9 years). The clinical characteristics of patients are shown
n Table 1. There were no significant differences between
atients with positive and negative EPS or between those
ith a normal MTWA and abnormal MTWA. The 4TWA test was positive, negative, and indeterminate in
6%, 29%, and 25%, respectively. The EPS was positive in
0%. Four hundred ninety-four patients (87%) completed at
east 1 year of follow-up, and 362 (64%) completed 2 years
f follow-up. Patients were categorized into 6 groups on the
asis of EPS and MTWA test results (Table 2). Overall,
7% of the total population received ICDs (495 of 566).
early all (97%) patients who were either MTWA or
PS received ICDs, as required by protocol. ICDs were
nserted in 67% of patients with a negative or indeterminate
TWA and a negative EPS.
vents. The 1- and 2-year event rates were 7.5% (n  39)
nd 14% (n  65), respectively. Of the 65 patients who met
he primary end point, 55 had appropriate ICD discharges
51 shocks and 4 antitachycardia pacing [ATP] therapies)
nd 10 had SCD (7 of these had inserted ICDs). Although
he protocol did not call for ATP therapy, 4 patients were
djudicated by the events committee to have met the
rimary end point because ATP therapy was delivered for
entricular tachycardia above the rate cutoff specified in the
rotocol. Therefore, these patients were included in the
nalyses.
omparison of noninvasive MTWA with invasive EPS
n predicting events. The mean difference in PPV at 1 year
etween the MTWA- (9.5%) and EPS-directed (11.1%)
trategies ( in Fig. 2) was 1.6%. Similarly, the mean
ifference in NPV at 1 year was 0.2% (95.3% for MTWA
s. 95.1% for EPS). Because all differences were within the
0% definition of noninferiority, the MTWA-directed
trategy was comparable to an EPS-directed strategy in
redicting the occurrence of the primary end point at 1 year
Fig. 2). The sensitivity and specificity of the MTWA-
irected strategy was 74% and 44% at 1 year and 66% and
EPS and MTWA risk stratification in 100% (n=566) 
Screened 629 subjects with CAD
LVEF < 0.40, NSVT, No previous VT/VF
63 Excluded
Follow up for events (n = 566)
ICD Implant required in EPS+ or TWA+ patients (97%)
Figure 1 Summary of Study Design
CAD  coronary artery disease; EPS  electrophysiological study; ICD 
implantable cardioverter-defibrillator; LVEF  left ventricular ejection fraction;
MTWA  microvolt T-wave alternans; NSVT  nonsustained ventricular
tachycardia.4% at 2 years, respectively. The EPS-directed strategy had
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ABCD Trial February 10, 2009:471–9sensitivity and specificity of 62% and 62% at 1 year and
4% and 63% at 2 years, respectively.
The pre-specified analysis comparing “positive/negative
TWA tests” (i.e., excluding indeterminate tests) with
linical Characteristics of Patients
Table 1 Clinical Characteristics of Patients
Clinical Characteristic Subjects (n  566)
Age (yrs) 65.4 10
Sex
Male 478 (84%)
Female 88 (16%)
NYHA functional class
I 172 (30%)
II 286 (51%)
III 107 (19%)
Unknown 1 (0.2%)
Mean LVEF 0.28  0.08
Cardiovascular history
Prior MI 422 (75%)
Prior CABG 325 (57%)
Prior PCI 263 (47%)
LV dysfunction due to CAD 369 (65%)
Angina 120 (21%)
Risk factors
Diabetes 174 (31%)
Hyperlipidemia 430 (75%)
Hypertension 358 (63%)
Family history of CAD 209 (37%)
Family history of SCD 22 (4%)
Cardiovascular symptoms
Chronic angina 77 (14%)
Dyspnea at rest 34 (6%)
Dyspnea with exertion 272 (48%)
Palpitations 101 (18%)
None 156 (27%)
Medical therapy
ACE inhibitor or ARB 501 (89%)
Beta-blocker 488 (86%)
Statin 457 (81%)
Diuretic 345 (61%)
Digoxin 190 (34%)
Calcium-channel blocker 61 (10%)
CE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; CABG  coronary
rtery bypass grafting; CAD coronary artery disease; LV left ventricular; LVEF left ventricular
jection fraction; MI  myocardial infarction; NYHA  New York Heart Association; PCI 
ercutaneous coronary intervention; SCD  sudden cardiac death.
Actuarial Event Rates by Group Assignment
Table 2 Actuarial Event Rates by Group Ass
Group Assignment Subjects
Subjects W
ICD Inserte
A: MTWA/EPS 166 153
B: MTWA/EPS 66 66
C: MTWA/EPS 94 94
D: MTWA/EPS 99 68
E: MTWA (Ind)/EPS 62 62
F: MTWA (Ind)/EPS 79 52
Total 566 495EPS  electrophysiological study; ICD  implantable cardioverter-defibrillatoPS also achieved noninferiority (95% upper confidence
imit for  was 4.8% and 6.7% for the PPV and 2.8% and
.7% for the NPV at 1 and 2 years, respectively).
imilarly, a pre-specified analysis comparing “abnormal/
ormal MTWA” with EPS also achieved noninferiority
95% upper confidence limit for  was 5.2% and 9.1% for
he PPV and 2.8% and 5.9% for the NPV at 1 and 2
ears, respectively). Importantly, neither of these defini-
ions depends on EPS to determine “positivity” of the
TWA strategy.
Pre-specified secondary analyses were performed to
etermine interactions between MTWA and EPS in
redicting events. As shown in Figure 3, many (55%)
atients had discordant test results. Importantly, the
vent rate in patients with 2 normal tests was approxi-
ately 3-fold lower than in patients with 1 abnormal test
nd approximately 6-fold lower than patients with 2
bnormal tests, suggesting that the 2 tests were comple-
entary in predicting outcomes (Fig. 3). Because 33% of
atients with both normal EPS and a normal MTWA
est did not receive an ICD, it is possible that the absence
f ICDs could have reduced detection of events in this
ubgroup of patients. Therefore, data were reanalyzed
fter excluding patients without ICDs. The 1-year event
ate remained low (3.2%) in the MTWA-normal/EPS-
egative group, reaffirming that the predictive value of
isk stratification was not substantially affected by varia-
ions in ICD use between groups.
The Kaplan-Meier event rates predicted by EPS and
TWA are shown in Figure 4. Time-dependent hazard
atios (HRs) (where HRs were estimated separately for
elow or above the stated time cutoff) are plotted with their
onfidence intervals as insets. Statistically significant HRs
p  0.05) are indicated by asterisks. The EPS was a
ignificant predictor of events starting at 9 months and for
he remainder of the follow-up period (Fig. 4A), with HRs
onsistently in the 2 to 3 range. In contrast, MTWA,
hether with the MTWA-directed or MTWA-normal/
bnormal definitions (Figs. 4B and 4C), was predictive of
linical outcomes earlier (at 6 months) than EPS but not
ater in the follow-up period (i.e., no longer predictive by 12
o 15 months).
ent
12-Month Event Rate
(Number of Events)
24-Month Event Rate
(Number of Events)
6.5% (10) 12.0% (17)
7.8% (5) 15.3% (9)
11.1% (10) 15.7% (13)
2.3% (2) 10.1% (7)
14.8% (7) 22.9% (13)
4.6% (3) 11.0% (6)
7.5% (39) 14.0% (65)ignm
ith
dr; Ind  indeterminate; MTWA  microvolt T-wave alternans.
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February 10, 2009:471–9 ABCD Trialiscussion
he ABCD trial provides a unique opportunity for com-
aring risk stratification strategies in a relevant and large
ohort of patients. We found that ICD insertion directed by
oninvasive MTWA testing is comparable to one guided by
PS in predicting the risk of ventricular tachyarrhythmias
r SCD in patients with coronary artery disease, LVEF
0.40, and NSVT. In addition, by using the tests in a
omplementary fashion, the efficiency of SCD prevention is
ncreased further.
Initial recommendations for ICD insertion for primary
revention of SCD included NSVT and inducibility at EPS
1,2). Such a strategy identifies a high-risk group of pa-
ients, but it is costly, invasive, and hence impractical for
road-based screening. Although EPS is no longer generally
sed for this purpose, excellent data show that the cost-
ffectiveness of primary prevention of SCD and reduction in
otal mortality are doubled if risk stratification is used to
uide ICD insertion (9,19). Therefore, despite the evolution
n practice standards, the results of the ABCD trial remain
ighly relevant to contemporary issues regarding optimal
election of patients for primary prevention of SCD. In fact,
he comparable predictive accuracy of noninvasive MTWA
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Figure 2 Comparison Between PPV and NPV
Comparison between positive predictive value (PPV) (top panels) and negative pre
DIR) at 12 months and 24 months of follow-up (mean [solid bar] and 95% confide
DIR). The 95% upper confidence limit for the difference in PPV was 4.2% at 1 year
tions as in Figure 1.esting carries significant clinical importance, because this iest can obviously be applied more broadly in clinical
ractice than EPS.
In support of the primary hypothesis of the ABCD trial, the
PV and NPV of an MTWA-directed strategy compared
ith EPS were essentially identical. The NPV of theMTWA-
irected strategy was 95% at 1 year (Fig. 2), similar to prior
TWA trials (13,20). This is most important, because the
linically relevant question today is who should not receive an
CD (i.e., who is at low enough risk where the risk of ICD
nsertion might outweigh its benefit). The PPV of MTWA
bserved in the ABCD trial was somewhat lower than ex-
ected compared with previous trials (12,13). One explanation
s that beta-blocker therapy was withheld before MTWA
esting, possibly converting some normal MTWA tests to
bnormal (21) in patients who did not experience events.
The event rates observed in ABCD were low and
emonstrate that, even in a population that for the most
art satisfies current indications for ICD insertion, the
bsolute risk of a ventricular tachyarrhythmic event is low.
n the basis of the MADIT 1 (Multicenter Automatic
efibrillator Trial) and MUSTT (Multicenter Unsustained
achycardia Trial) annualized ICD shock rates (30% and
7%, respectively), we estimated that the overall event rate
EPS MTWA DIR
EPS MTWA DIR
∆ = 2.4%
24 Months
∆ = 0.8%
24 Months
value (NPV) (bottom panels) of EPS and MTWA-directed ICD insertion (MTWA
tervals [error bars] are shown;   mean difference between EPS and MTWA
.8% at 2 years and, for the NPV, 2.1% at 1 year and 4.3% at 2 years. Abbrevia-lue
alue
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nce in
and 5n the ABCD trial would be approximately 25% at 1 year.
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ABCD Trial February 10, 2009:471–9he actual overall event rate for the end point of ICD
ischarges or SCD was only 7.5% and 14% at 1 and 2 years,
espectively. The low event rate reduced the power of the
tudy to prove the primary hypothesis, because it could have
asked the detection of differences in PPV and NPV
etween EPS and MTWA. This is an important limitation
f the ABCD trial and other trials designed to show
oninferiority. Unfortunately, the requirements for demon-
trating noninferiority of new diagnostic tests, especially in
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ocus of considerable debate in the published statistical
iterature.
Although not a primary end point of the ABCD trial,
ppropriate ICD discharges or total mortality were still
ower than expected (11% and 19%, respectively) but com-
arable to those of recently published studies on MTWA.
ore recently, the MADIT II (4) and SCD-HeFT (Sud-
en Cardiac Death in Heart Failure Trial) (5) studies
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February 10, 2009:471–9 ABCD Trialemonstrated annualized appropriate ICD therapy rates of
2% and 7.3%, respectively. The event rates of the ABCD
rial are in close agreement with the SCD-HeFT study,
ecause in both trials ATP was programmed off per proto-
ol, as opposed to MADIT II, where 40% of all ICD
ischarges were related to ATP.
A majority of patients (55%) manifested discordant
TWA and EPS results, suggesting that the 2 tests might
ssess different components of the arrhythmogenic sub-
trate. Interestingly, the 2 tests were complementary in
redicting risk (Fig. 3), because subjects testing negative for
oth markers were at considerably lower risk than those
esting positive by 1 marker or by both markers. It is
oteworthy that the 1-year event rate of patients with
egative MTWA and negative EPS was only 2.3% and
emained low (3.2%) even after excluding from analysis the
3% of these patients who did not receive ICDs. These data
uggest that multiple risk markers used in combination
ight improve our ability to identify high- and low-risk
atients and improve the therapeutic efficiency of SCD
revention.
An aim of the ABCD trial was to determine whether
trategies incorporating MTWA, alone or in combination
ith EPS—in addition to low LVEF—would enable phy-
icians to better identify patients at the highest and lowest
isk of SCD. Although the definitive answer to this question
waits randomized clinical trials, a strength of the ABCD
rial is that all patients underwent screening with both
TWA and EPS. This provided a unique opportunity to
ompare the effectiveness of these markers in identifying
andidates for primary prevention of SCD. Table 3 shows
he outcomes derived from the 1-year event rate, had several
otential clinical strategies been applied to the ABCD trial
opulation. Unique insights into the risk and benefit of each
otential strategy are provided. In agreement with previous
CD trials, the ABCD trial demonstrated that a strategy of
nserting ICDs on the basis of a low LVEF alone results in
he vast majority (93%) of ICD recipients not receiving
herapy after 1 year (Table 3, “LVEF alone” strategy). This
s relevant to current clinical practice, because 86% of
BCD patients had an LVEF 0.35 and therefore qualify
or ICD insertion on the basis of current indications.
omparison of the Performance of Various Potential Risk Stratificaro the Pre-Specifi d 1-Year Primary End int Event Rate (n  3
Table 3 Comparison of the Performance of Various Potential RFrom the Pre-Specified 1-Year Primary End Point Event
Risk Stratification Strategy
Patients Undergoing
Risk Stratification (%)
MTWA EPS
EPS alone 0% 100%
MTWA-directed 100% 25%
MTWA normal/abnormal alone 100% 0%
EPS and MTWA combined 100% 29%
LVEF alone None None
MTWA-Directed”: all patients would undergo an MTWA test and go on to EPS only if MTWA was in
f the MTWA was normal (see text for discussion).
Abbreviations as in Tables 1 and 2.By contrast, risk-stratifying all ABCD patients by EPS
lone (Table 3, “EPS alone” strategy) would have resulted in
44 patients not receiving an ICD (60% with a normal
PS). After 1 year of follow-up, such a strategy would have
mproved therapeutic efficiency (9 ICDs inserted to save 1
ife compared with 15 with “LVEF alone” strategy), but 15
otentially untreated patients would have experienced a
rimary end point event. A strategy based on an “abnormal”
TWA alone (i.e., inserting ICDs in patients with a
ositive or indeterminate MTWA test) would have resulted
n 165 patients not receiving an ICD (29% with a normal
TWA test). This strategy would also improve therapeutic
fficiency compared with the “LVEF alone” strategy (13 vs.
5 ICDs inserted to save 1 life), whereas only 7 potentially
ntreated patients would have experienced a primary end
oint event at 1 year (Table 3, “MTWA normal/abnormal”
trategy). Because of the complementary prognostic value of
PS and MTWA (Fig. 3), combining the 2 tests can
urther enhance risk stratification. For example, if one
pplied the “MTWA-directed” strategy to guide ICD
nsertion (Table 3, “MTWA-directed” strategy), 244 pa-
ients (43%) would forego ICD insertion, and 10 potentially
ntreated patients would experience a primary end point
vent at 1 year. With such a strategy, only 25% of patients
ould undergo an EPS (those with an indeterminate
TWA test) and 11 ICDs would be inserted to save 1 life.
inally, if one wanted to adopt the most conservative and
afest strategy of foregoing ICD insertion only if both
TWA and EPS were normal, one could insert ICDs in all
TWA-abnormal patients and go on to an EPS in the 29%
f patients with a normal MTWA to guide ICD insertion
Table 3, “EPS/MTWA combined” strategy). With such a
trategy, one would forego ICD insertion in only 99 patients
17%) and insert 13 ICDs to save 1 life, whereas only 2
ntreated patients would experience an event.
The preceding discussion is based on the assumption that
CDs are always effective in preventing SCD and that ICD
nsertion has no associated risk. However, 7 of the 10 SCD
vents occurred in patients “protected” by an ICD, suggest-
ng that not all SCD is preventable. The acceptable thresh-
ld to determine which patients should be treated as
pposed to those who need treatment is ultimately a societal
Strategies Derivedf he ABCD Population (n  566)
tratification Strategies Derived
(n  39) of the ABCD Population (n  566)
Potential Number of
Patients With ICDs
Potential Number of
Patients Without ICDs
Event Event Event Event
24 198 15 329
29 293 10 234
32 369 7 158
37 430 2 97
39 527 None None
inate; “EPS and MTWA combined”: all patients would undergo MTWA test and go on to EPS onlytion9) o
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ABCD Trial February 10, 2009:471–9ecision. In the end, the clinician must consider which
trategy is most appropriate for each individual patient,
epending on comorbidities, potential risk of ICD insertion
tself, willingness of the patient to undergo insertion, and
he risk of SCD weighed against the competing risk of
onsudden or noncardiac death.
Our results also show that the predictive values of EPS
nd MTWA were time-dependent. As shown in Figure 4,
he Kaplan-Meier event rates converge and the HRs de-
rease over time (particularly after 1 year) for MTWA and,
o a lesser degree, for EPS. In fact, the NPV of MTWA at
years is significantly reduced. Because arrhythmic risk
hanges over time due to changes in the arrhythmogenic
ubstrate, it is not surprising that the predictive accuracy of
risk marker would diminish over time. Although unique
nd interesting, the time-varying prediction of outcomes
eeds to be interpreted with caution. The trial was not
owered to assess end points beyond 1 year, because only
62 of 566 patients (64%) reached the 2-year follow-up
oint. Moreover, the apparent loss of predictive value of
TWA beyond 1 year was not observed in other trials (12),
hich relied on mortality rather than on ICD-related end
oints, raising concerns that the use of surrogate end points
ather than the MTWA’s ability to track relevant end points
ight explain the lack of correlation over longer time
eriods. Nonetheless, these data suggest that sequential
rofiling of arrhythmic risk over time might be appropriate
nd, specifically, that MTWA testing and/or other risk
tratifiers might need to be repeated at regular intervals.
imitations of the trial. The ABCD trial patients were
elected on the basis of LVEF 0.40, raising the possibility
hat these patients might have been at somewhat lower risk
han those currently selected for ICD insertion on the basis
f LVEF0.35 (4,5). Moreover, because heart rate must be
levated gradually to measure MTWA, exclusion of patients
ith atrial fibrillation, chronotropic incompetence, and
ntolerance to exercise could have further reduced the event
ate in our population. However, the LVEF selection
riteria probably did not substantially lower risk, because
nly 77 patients had LVEF0.35, and other factors such as
he requirement for NSVT might actually have increased
he population’s risk. The comparable event rates measured
n the ABCD trial and in earlier primary prevention trials
uggest that the ABCD trial patients possessed a similar risk
rofile as the patients in those trials.
The ABCD trial used a combined end point of “ICD
ischarge or SCD,” which might have overestimated the
ctual SCD rate by 2-fold (22) compared with studies using
otal mortality as an end point. Because most patients (87%)
eceived ICDs (i.e., a very sensitive detector of events)
rogrammed in a consistent fashion, one can argue that by
verestimating the number of SCD events, the ABCD trial
nderestimated the potential NPV that could be achieved
y MTWA testing. This highlights an important limitation
f surrogate end points derived from ICDs. These argu-ents serve to emphasize the importance of future random-
zed risk stratification trials using mortality end points.
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APPENDIX
or participants in the ABCD trial,
lease see the online version of this article.
